Therapy Areas: AIDS & HIV
US President's medical adviser expects COVID-19 vaccination with AstraZeneca shot to be accepted for US travel
21 September 2021 -

Dr Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases and the US President's chief medical adviser, has said that he believes the AstraZeneca (LON:AZN) COVID-19 vaccine should be accepted by the US under its new travel rules, BBC News reported on Tuesday.

Currently, the US regulator does not recommend the AstraZeneca vaccine for use in the US.

However Dr Fauci said he knows there is a lot of data available on the vaccine.

Dr Fauci told BBC Radio 4's Today programme that given the fact the situation in the US is comparable with so many other countries, including the UK, the government wants to have a uniform policy of requiring vaccinations and testing.

Also, Dr Fauci added that the sooner the world gets vaccinated the "greater the chance we will get of not allowing variants to emerge".

According to Dr Fauci, it is less to do with travel and more to do with getting everyone vaccinated.

Login
Username:

Password:


Related Headlines

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the US government for the Treatment or Post-Exposure Prevention of COVID-19

Adaptive Phage Therapeutics Inks Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Venatorx Pharmaceuticals Forges Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

US likely to make available COVID-19 vaccines for children between five to 11 in November 2021

US President's chief medical adviser says US can prevent another COVID-19 surge with higher vaccination rates

The IMA Group strengthens and broadens clinical research offerings via acquisition of DXRG

US FDA Approves Ocular Therapeutix Supplemental New Drug Application for Dextenza 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Vedanta Touts Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of USD 23.8m Option by BARDA

First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics doses first COVID-19 patient under Phase 3 SAB-185 NIH ACTIV-2 trial

Malaysia's drugs regulator approves Sinovac's COVID-19 vaccine for 12-17 year olds

SAB announces interim analysis of SAB-185 in phase 2 part of ACTIV-2 study in hospitalized patients with mild to moderate COVID-19